prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Department Clinical Pharmacy and Pharmacology University Medical Center Groningen Groningen

Lilly’s Tirzepatide Slowed Kidney Function Decline in High Risk Diabetics with Heart Disease

MedicalResearch.com Interview with:

prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Department Clinical Pharmacy and Pharmacology University Medical Center Groningen Groningen

Prof. Heerspink

prof. dr. H.J. (Hiddo) Lambers Heerspink
Clinical Pharmacologist
Department Clinical Pharmacy and Pharmacology
University Medical Center Groningen
Groningen 

MedicalResearch.com:  What is the background for this study?   

Response: Tirzepatide is a novel GIP-GLP1 receptor agonist recently FDA approved for the treatment of type 2 diabetes. The SURPASS_4 trial demonstrated that in patients with type 2 diabetes at high cardiovascular risk tirzepatide compared to insulin glargine markedly reduces Hba1c and body weight. About 1 out of 3 patients with type 2 diabetes and CV disease has kidney disease and these patients are at high risk of kidney failure. The aim of this study was to assess whether tirzepatide could slow CKD progression in high risk individuals with type 2 diabetes participating in the SURPASS 4 trial. 

MedicalResearch.com:  What are the main findings?

Response:  The main findings were that tirzepatide indeed significantly reduced albuminuria (a strong renal and cardiovascular risk marker), reduced eGFR decline compared to insulin glargine and reduced the risk of a composite kidney endpoint of new-onset macroalbuminuria, 40% eGFR decline, end-stage kidney disease and renal death. These data suggest that tirzepatide may confer kidney protection and support future trials to provide more definitive evidence. 

MedicalResearch.com: What should readers take away from your report?

Response: The main message from this study is that a novel GIP-GLP-1RA does not only reduce HbA1c and body weight but also slows the decline in kidney function in high risk patients with type 2 diabetes and CV disease. Readers should realize that these data are generated as part of an exploratory analysis and can not yet be interpreted as definitive evidence but they support additional research to confirm the kidney protective effects of tirzepatide.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: A large dedicated renal outcome trial should be conducted

My disclosures are that I am a consultant to Eli-Lilly

Citation:

American Diabetes Associations 2022 Meeting

Source Reference: Heerspink HL, et al “Effects of tirzepatide vs. insulin glargine 100 U/mL on kidney outcomes in participants with type 2 diabetes in SURPASS-4” ADA 2022; Abstract 17-OR.

[wysija_form id=”3″]

Jun 8, 2022 @ 12:24 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. Some links may be sponsored and no links are warranted or endorsed by MedicalResearch.com or its parent company, Eminent Domains Inc. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Please follow and like us: